TRYP THERAPEUTICS SUBMITS IND APPLICATION FOR PHASE 2A CLINICAL TRIAL IN EATING DISORDERS
Can shrooms treat this rare genetic disorder?
Tryp Therapeutics (TRYP) is preparing for a Phase 2a study on overeating disorders including a rare condition called Prader-Willi Syndrome, a genetic disorder that causes intellectual disability, shortness in height, and constant hunger than often leads to obesity and diabetes.
The clinical trial is expected to begin in Q4 of this year and will investigate various other eating disorders such as binge eating and hypothalamic obesity. Ten patients will be given two doses of psilocybin, which in theory will increase neuroplasticity to create healthier neural patterns related to eating habits.
The San Diego company just filed a Investigational New Drug (IND) application with the FDA, for TRP-8802, the psilocybin formulation that will be used in the study.